Literature DB >> 8463997

Characterization of [3H]SK&F 108566 as a radioligand for angiotensin type-1 receptor.

N Aiyar1, E Griffin, A Shu, R Heys, D J Bergsma, J Weinstock, R Edwards.   

Abstract

Rat aortic smooth muscle cells were used as a model system to characterize the binding properties of [3H]SK&F 108566, an angiotensin type-1 (AT1) receptor antagonist. The binding was specific, saturable and reversible. The association and dissociation rates of [3H]SK&F 108566 binding to smooth muscle cells were monophasic and Scatchard analysis of equilibrium binding data yielded a linear plot indicating a homogenous population of binding sites. The maximum binding (Bmax) and apparent dissociation constant (Kd) were 22,000 +/- 6000 sites/cell and 0.83 +/- 0.08nM respectively. The pharmacological specificity of [3H]SK&F 108566 binding to smooth muscle cells is consistent with that observed for AT1 and confirms AT1 receptor specificity of this radioligand. High affinity binding was observed in membranes prepared from bovine adrenal cortex, rat liver and rat kidney glomeruli. COS cells transfected with cDNA encoding human AT1 angiotensin II receptors also displayed high affinity binding site for [3H]SK&F 108566. No specific binding could be detected on membranes prepared from bovine cerebellum, a tissue rich in the angiotensin type-2 (AT2) receptor. These observations indicate that [3H]SK&F 108566 binds to sites which have pharmacological characteristics of angiotensin II AT1 subtype receptors and can be used as a subtype-selective radioligand to characterize AII receptors in various systems.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8463997     DOI: 10.3109/10799899309073697

Source DB:  PubMed          Journal:  J Recept Res        ISSN: 0197-5110


  5 in total

Review 1.  Eprosartan.

Authors:  K J McClellan; J A Balfour
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

Review 2.  Eprosartan: a review of its use in the management of hypertension.

Authors:  G L Plosker; R H Foster
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 3.  Eprosartan: a review of its use in the management of hypertension.

Authors:  Gayle W Robins; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Estrogen Metabolite 2-Methoxyestradiol Attenuates Blood Pressure in Hypertensive Rats by Downregulating Angiotensin Type 1 Receptor.

Authors:  Yong Zhang; Benard O Ogola; Laxmi Iyer; Vardan T Karamyan; Thomas Thekkumkara
Journal:  Front Physiol       Date:  2022-05-02       Impact factor: 4.755

Review 5.  Eprosartan: a review of its use in hypertension.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.